Continued work will better assess the therapeutic potential of CD6 blockade in both mouse models (e.g., starting treatment after the onset of disease) and human subjects to determine whether inhibiting this pathway is a viable strategy for the treatment of LN and/or SLE. This evidence concerns the gene CD6 and systemic lupus erythematosus.